InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
OtherDisclosed buys
0
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Knappertz Volker. Officer active across 2 companies, notably GW Pharmaceuticals PLC. In total, 4 reports have been logged. Split: 0 buy · 2 sells. Total volume traded: €156k. History available since 2 March 2023. The latest transaction was disclosed on 27 February 2024 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Knappertz Volker
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
4,930 shares@ US$6.1017.8% of flowCommon StockSEC:0001600620-24-000028:0
25,146 shares@ US$5.4882.2% of flowCommon StockSEC:0001600620-24-000022:0
191,462 shares0Common StockSEC:0001628280-23-006527:0
92,412 sharesOrdinary SharesSEC:0000899243-21-018663:0
4 of 4 declarations
About Knappertz Volker
Knappertz Volker is EVP, Research and Development at Aurinia Pharmaceuticals Inc. (XNAS) and Chief Medical Officer at GW Pharmaceuticals PLC (XNAS). The record shows 5 filings in total. Among the 5 sampled recent filings, the modal transaction nature is sell, with total sales amounting to EUR 155599 between 2021-05-07 and 2024-02-29.
